Compare Novartis AG (NVS) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Snap On Incorporated — how do they compare? Novartis AG trades at $142.74 (market cap $274.00B), while Snap On Incorporated trades at $360.27 (market cap $18.62B). The key difference: Novartis AG is far larger — about 14.7× Snap On Incorporated's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Snap On Incorporated for 36 Days on average.
| NVS | SNA | |
|---|---|---|
Market Cap | $274.00B | $18.62B |
Volume | 1,852,137 | 360,121 |
Sector | Health | Industrials |
52-Week High | $168.62 | $419.31 |
52-Week Low | $121.80 | $327.33 |
Typical Hold Time | 82 Days | 36 Days |
Enterprise Value | $315.32B | $18.25B |
Dividend Yield | 3.31% | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Snap-on Incorporated (SNA) trades at $359.89, down 2.37% on the day, with a bearish technical signal from moving averages and oscillators. Fundamentally, the company maintains strong profitability with a 19.6% net income margin and a 17.58% ROE, though Q1 2026 earnings slightly missed expectations. Recent news highlights gross margin expansion and institutional position adjustments.
The outlook is supported by analyst consensus with a $449 price target and 66.7% buy ratings, but risks include valuation premiums and mixed segment trends. Earnings growth from innovation and RCI initiatives remains a key catalyst, though integration costs and softer OEM demand pose execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
